296 related articles for article (PubMed ID: 32002591)
1. Influence of localization of PSMA-positive oligo-metastases on efficacy of metastasis-directed external-beam radiotherapy-a multicenter retrospective study.
Schmidt-Hegemann NS; Kroeze SGC; Henkenberens C; Vogel MME; Kirste S; Becker J; Burger IA; Derlin T; Bartenstein P; Eiber M; Mix M; la Fougère C; Müller AC; Grosu AL; Combs SE; Christiansen H; Guckenberger M; Belka C
Eur J Nucl Med Mol Imaging; 2020 Jul; 47(8):1852-1863. PubMed ID: 32002591
[TBL] [Abstract][Full Text] [Related]
2. Outcome after PSMA-PET/CT-based salvage radiotherapy for nodal recurrence after radical prostatectomy.
Rogowski P; Trapp C; von Bestenbostel R; Eze C; Ganswindt U; Li M; Unterrainer M; Zacherl MJ; Ilhan H; Beyer L; Kretschmer A; Bartenstein P; Stief C; Belka C; Schmidt-Hegemann NS
Eur J Nucl Med Mol Imaging; 2022 Mar; 49(4):1417-1428. PubMed ID: 34628521
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of PSMA ligand PET-based radiotherapy for recurrent prostate cancer after radical prostatectomy and salvage radiotherapy.
Oehus AK; Kroeze SGC; Schmidt-Hegemann NS; Vogel MME; Kirste S; Becker J; Burger IA; Derlin T; Bartenstein P; Eiber M; Mix M; la Fougère C; Belka C; Combs SE; Grosu AL; Müller AC; Guckenberger M; Christiansen H; Henkenberens C
BMC Cancer; 2020 Apr; 20(1):362. PubMed ID: 32349700
[TBL] [Abstract][Full Text] [Related]
4. PSMA-PET/CT-guided salvage radiotherapy in recurrent or persistent prostate cancer and PSA < 0.2 ng/ml.
Solomonidou N; Germanou D; Strouthos I; Karagiannis E; Farolfi A; Koerber SA; Debus J; Peeken JC; Vogel ME; Vrachimis A; Spohn SKB; Shelan M; Aebersold D; Grosu AL; Ceci F; Kroeze SGC; Guckenberger M; Fanti S; Belka C; Hruby G; Scharl S; Wiegel T; Bartenstein P; Henkenberens C; Emmett L; Schmidt-Hegemann NS; Ferentinos K; Zamboglou C
Eur J Nucl Med Mol Imaging; 2023 Jul; 50(8):2529-2536. PubMed ID: 36905411
[TBL] [Abstract][Full Text] [Related]
5. Prognostic risk classification for biochemical relapse-free survival in patients with oligorecurrent prostate cancer after [
Vogel MME; Kroeze SGC; Henkenberens C; Schmidt-Hegemann NS; Kirste S; Becker J; Burger IA; Derlin T; Bartenstein P; Mix M; la Fougère C; Eiber M; Christiansen H; Belka C; Grosu AL; Müller AC; Guckenberger M; Combs SE
Eur J Nucl Med Mol Imaging; 2020 Sep; 47(10):2328-2338. PubMed ID: 32179961
[TBL] [Abstract][Full Text] [Related]
6. Outcome after PSMA PET/CT based radiotherapy in patients with biochemical persistence or recurrence after radical prostatectomy.
Schmidt-Hegemann NS; Fendler WP; Ilhan H; Herlemann A; Buchner A; Stief C; Eze C; Rogowski P; Li M; Bartenstein P; Ganswindt U; Belka C
Radiat Oncol; 2018 Mar; 13(1):37. PubMed ID: 29499730
[TBL] [Abstract][Full Text] [Related]
7. The prognostic significance of a negative PSMA-PET scan prior to salvage radiotherapy following radical prostatectomy.
Adebahr S; Althaus A; Scharl S; Strouthos I; Farolfi A; Serani F; Lanzafame H; Trapp C; Koerber SA; Peeken JC; Vogel MME; Vrachimis A; Spohn SKB; Grosu AL; Kroeze SGC; Guckenberger M; Fanti S; Hruby G; Emmett L; Belka C; Schmidt-Hegemann NS; Henkenberens C; Aebersold DM; Wiegel T; Afshar-Oromieh A; Zamboglou C; Shelan M
Eur J Nucl Med Mol Imaging; 2024 Jan; 51(2):558-567. PubMed ID: 37736808
[TBL] [Abstract][Full Text] [Related]
8. The maximum standardized uptake value in patients with recurrent or persistent prostate cancer after radical prostatectomy and PSMA-PET-guided salvage radiotherapy-a multicenter retrospective analysis.
Spohn SKB; Farolfi A; Schandeler S; Vogel MME; Ruf J; Mix M; Kirste S; Ceci F; Fanti S; Lanzafame H; Serani F; Gratzke C; Sigle A; Combs SE; Bernhardt D; Gschwend JE; Buchner JA; Trapp C; Belka C; Bartenstein P; Unterrainer L; Unterrainer M; Eiber M; Nekolla SG; Schiller K; Grosu AL; Schmidt-Hegemann NS; Zamboglou C; Peeken JC
Eur J Nucl Med Mol Imaging; 2022 Dec; 50(1):218-227. PubMed ID: 35984452
[TBL] [Abstract][Full Text] [Related]
9. Detection level and pattern of positive lesions using PSMA PET/CT for staging prior to radiation therapy.
Schmidt-Hegemann NS; Fendler WP; Buchner A; Stief C; Rogowski P; Niyazi M; Eze C; Li M; Bartenstein P; Belka C; Ganswindt U
Radiat Oncol; 2017 Nov; 12(1):176. PubMed ID: 29126446
[TBL] [Abstract][Full Text] [Related]
10. Metastasis-Free Survival and Patterns of Distant Metastatic Disease After Prostate-Specific Membrane Antigen Positron Emission Tomography (PSMA-PET)-Guided Salvage Radiation Therapy in Recurrent or Persistent Prostate Cancer After Prostatectomy.
Zamboglou C; Strouthos I; Sahlmann J; Farolfi A; Serani F; Medici F; Cavallini L; Morganti AG; Trapp C; Koerber SA; Peeken JC; Vogel MME; Schiller K; Combs SE; Eiber M; Vrachimis A; Ferentinos K; Spohn SKB; Kirste S; Gratzke C; Ruf J; Grosu AL; Ceci F; Fendler WP; Miksch J; Kroeze S; Guckenberger M; Lanzafame H; Fanti S; Hruby G; Wiegel T; Emmett L; Schmidt-Hegemann NS; Henkenberens C
Int J Radiat Oncol Biol Phys; 2022 Aug; 113(5):1015-1024. PubMed ID: 35659629
[TBL] [Abstract][Full Text] [Related]
11. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
12. Prostate-specific Membrane Antigen Positron Emission Tomography-detected Oligorecurrent Prostate Cancer Treated with Metastases-directed Radiotherapy: Role of Addition and Duration of Androgen Deprivation.
Kroeze SGC; Henkenberens C; Schmidt-Hegemann NS; Vogel MME; Kirste S; Becker J; Burger IA; Derlin T; Bartenstein P; Eiber M; Mix M; la Fougère C; Christiansen H; Belka C; Combs SE; Grosu AL; Müller AC; Guckenberger M
Eur Urol Focus; 2021 Mar; 7(2):309-316. PubMed ID: 31495759
[TBL] [Abstract][Full Text] [Related]
13. Use of gallium-68 prostate-specific membrane antigen positron-emission tomography for detecting lymph node metastases in primary and recurrent prostate cancer and location of recurrence after radical prostatectomy: an overview of the current literature.
Luiting HB; van Leeuwen PJ; Busstra MB; Brabander T; van der Poel HG; Donswijk ML; Vis AN; Emmett L; Stricker PD; Roobol MJ
BJU Int; 2020 Feb; 125(2):206-214. PubMed ID: 31680398
[TBL] [Abstract][Full Text] [Related]
14. PSMA-positive nodal recurrence in prostate cancer : Salvage radiotherapy is superior to salvage lymph node dissection in retrospective analysis.
Schmidt-Hegemann NS; Buchner A; Eze C; Rogowski P; Schaefer C; Ilhan H; Li M; Fendler WP; Bartenstein P; Ganswindt U; Stief C; Belka C; Kretschmer A
Strahlenther Onkol; 2020 Jul; 196(7):637-646. PubMed ID: 32211942
[TBL] [Abstract][Full Text] [Related]
15. Prospective evaluation of
Dong L; Zhu Y; Xin M; Dong B; Pan J; Liu J; Amend SR; Xue W; Pienta KJ; Rowe SP
Med Oncol; 2020 Sep; 37(10):89. PubMed ID: 32920666
[TBL] [Abstract][Full Text] [Related]
16. Site-specific relapse patterns of patients with biochemical recurrence following radical prostatectomy assessed by
Devos G; Witters M; Moris L; Van den Broeck T; Berghen C; Devlies W; De Meerleer G; Goffin K; Jentjens S; Albersen M; Van Poppel H; Everaerts W; Joniau S
World J Urol; 2021 Feb; 39(2):399-406. PubMed ID: 32417995
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of repeated PSMA PET-directed radiotherapy for oligorecurrent prostate cancer after initial curative therapy.
Henkenberens C; Oehus AK; Derlin T; Bengel F; Ross TL; Kuczyk MA; Janssen S; Christiansen H; von Klot CAJ
Strahlenther Onkol; 2020 Nov; 196(11):1006-1017. PubMed ID: 32399639
[TBL] [Abstract][Full Text] [Related]
18. Stereotactic Body Radiotherapy for Oligometastatic Prostate Cancer Detected via Prostate-specific Membrane Antigen Positron Emission Tomography.
Kneebone A; Hruby G; Ainsworth H; Byrne K; Brown C; Guo L; Guminski A; Eade T
Eur Urol Oncol; 2018 Dec; 1(6):531-537. PubMed ID: 31158100
[TBL] [Abstract][Full Text] [Related]
19. Changes in Management After
Ng M; Guerrieri M; Wong LM; Taubman K; Sutherland T; Benson A; Byrne G; Koschel S; Yap K; Starmans M; Ong G; Macleod C; Foo M; Chao M
J Nucl Med; 2022 Sep; 63(9):1343-1348. PubMed ID: 35058320
[TBL] [Abstract][Full Text] [Related]
20. Efficacy, Predictive Factors, and Prediction Nomograms for
Rauscher I; Düwel C; Haller B; Rischpler C; Heck MM; Gschwend JE; Schwaiger M; Maurer T; Eiber M
Eur Urol; 2018 May; 73(5):656-661. PubMed ID: 29358059
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
